Early evidence suggests GLP-1s were linked to lower risks of developing substance use disorders — from alcohol to opioids — and to fewer overdoses and deaths in people with existing addictions.

Understanding what the US spends to treat mental health and substance use disorders (SUD) is important for understanding spending patterns and informing health policy. In this study, we determined ...

There’s ‘no evidence’ marijuana works to treat most mental health disorders, largest review of its kind finds - More than 52 ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, ...

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, affecting 12%–13% of adolescents in the United States, according to some studies. The pattern of inattention, ...

Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more ...

The FDA has not approved leucovorin for the treatment of autism, though some experts are still seeing an increase in prescription requests.

A large epidemiological study of more than 600,000 veterans with diabetes suggests GLP-1 weight-loss medications may reduce ...

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, affecting 12%–13% of adolescents in the United States, according to some studies.

Between four and 10 million people in the U.S. have fibromyalgia. Many doctors look askance at the disorder, leading some ...

Ryan Paige has called Biddeford home his entire life. He grew up in the city, attended its schools and spent time with ...

The Food and Drug Administration on Tuesday approved a generic medication for a rare brain disorder, while walking back suggestions by President Donald Trump and other administration officials that ...